REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Triple GH Stack

GH Optimizationadvanced

88

synergy

88
Share
Peptides

3

Avg Daily mcg

957

Level

advanced

Added

May 17, 2026

Overview

The Triple GH Stack amplifies the classic CJC-1295 + Ipamorelin protocol with Sermorelin, adding a third GHRH-pathway stimulant to maximize pituitary priming and increase the duration of GH stimulation beyond what CJC-1295 alone provides. Sermorelin is the shortest functional GHRH analog — a 29-amino acid truncated version of native GHRH. Where CJC-1295 provides a longer-acting GHRH signal, Sermorelin provides a more physiologically rapid, native-pattern pulse. Together they create a layered stimulation pattern: Sermorelin fires first with a sharp, natural signal, while CJC-1295 extends and sustains the pituitary response over a longer window. Ipamorelin continues to provide ghrelin-pathway amplification, ensuring the pituitary primed by CJC-1295 and Sermorelin releases its maximum GH payload with each pulse. The result is higher peak GH secretion and more frequent physiological pulses throughout the day and night. The 5-days-on/2-days-off cycling on Sermorelin (typically weekdays, off weekends) preserves receptor sensitivity on the GHRH pathway and prevents the tachyphylaxis that can occur with continuous stimulation. This stack is used by advanced practitioners seeking maximum GH axis stimulation without exogenous HGH. Blood work monitoring (IGF-1, fasting glucose) every 6–8 weeks is essential.

Dosing Protocol

CJC-1295

Every day· subcutaneous

Read more about CJC-1295 →

300 mcg

per dose

Ipamorelin

Every day· subcutaneous

Read more about Ipamorelin →

300 mcg

per dose

Sermorelin

5 days on/2 off· subcutaneous

Read more about Sermorelin →

500 mcg

per dose

Goals & Evidence

Maximum GH outputAnti-agingBody compositionLean muscleRecovery
Evidence tier:Human Data

Warnings

  • Multi-GHRH stacking increases risk of pituitary receptor downregulation. Cycle carefully and monitor IGF-1 levels.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.